Table 5.
Details of secondary transplants
| Sample | Fraction | Secondary recipients* | Tertiary recipients* | Time in vivo, weeks† |
|---|---|---|---|---|
| 3 | CD34−CD38+ | 4/4 | 5/5 | 31 |
| 3 | CD34−CD38− | 2/2 | NT | 26 |
| 7 | CD34−CD38+ | 5/5 | 5/5 | 12 |
| 9 | CD34−CD38+ | 3/3 | NT | 34 |
| 9 | CD34−CD38− | 1/1 | NT | 34 |
| 17 | CD34−CD38+ | 3/3 | NT | 24 |
| 17 | CD34−CD38− | 3/3 | NT | 24 |
| 17 | CD34+CD38+ | 3/3 | NT | 18 |
| 17 | CD34+CD38− | 1/1 | NT | 25 |
| 26 | CD34−CD38+ | 3/3 | NT | 24 |
| 26 | CD34−CD38− | 4/4 | NT | 24 |
| 26 | CD34+CD38+ | 4/4 | NT | 24 |
| 26 | CD34+CD38− | 0/1 | NT | 24 |
| 24 | CD34−CD38+ | 1/1 | NT | 24 |
| 24 | CD34−CD38− | Mouse died | NT | 24 |
| 24 | CD34+CD38+ | 1/1 | NT | 24 |
| 24 | CD34+CD38− | 1/1 | NT | 24 |
NT indicates not tested.
*
Data for secondary and tertiary recipients are reported as mice with AML/mice transplanted.
†
Time in vivo refers to the time from transplantation in the primary recipient to the termination of the final recipient. Sample 7 is very aggressive clinically and mice became sick due to leukemia 3 to 5 weeks after transplantation, hence the relatively short duration.